8-K: Phibro Animal Health Soars on Strong Q2, Raises FY26 Outlook

Phibro Animal Health Corporation reported robust second-quarter results, driven by strong sales across its Animal Health segment, leading to a significant increase in net income and an upward revision of its full-year fiscal 2026 financial guidance.

Summary

• Net sales increased 21% to $373.9 million for the second fiscal quarter ended December 31, 2025, compared to the prior year.
• Net income surged to $27.5 million, an increase of $24.3 million from the three months ended December 31, 2024.
• Diluted earnings per share rose to $0.67, an increase of $0.59 compared to the prior year period.
• Adjusted EBITDA grew 41% to $68.1 million for the quarter.
• Adjusted diluted EPS increased 58% to $0.87.
• Fiscal year 2026 guidance has been raised, with net sales now projected between $1.45 billion and $1.50 billion, and Adjusted EBITDA between $245 million and $255 million.
• The Animal Health segment's net sales increased $60.6 million, or 26%, primarily due to $57.5 million in incremental revenues from the MFA portfolio acquired on October 31, 2024.
• Gross margin improved by 260 basis points to 35.5% of net sales.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, reflecting strong operational execution, successful integration of an acquisition, and increased confidence in future financial performance, leading to raised guidance.

Positives

• Net sales increased by $64.6 million, or 21%, to $373.9 million for the quarter.
• Net income increased by $24.3 million to $27.5 million.
• Diluted earnings per share increased by $0.59 to $0.67.
• Adjusted EBITDA increased by $19.9 million, or 41%, to $68.1 million.
• Adjusted net income increased by $13.5 million, or 60%, to $35.7 million.
• Adjusted diluted EPS increased by $0.32, or 58%, to $0.87.
• Fiscal year 2026 guidance for net sales raised to $1.45 billion to $1.50 billion (14% growth at midpoint).
• Fiscal year 2026 guidance for Adjusted EBITDA raised to $245 million to $255 million (36% growth at midpoint).
• Animal Health segment net sales increased $60.6 million, or 26%, driven by $57.5 million from the newly integrated MFA portfolio.
• Nutritional specialty products sales increased 9% primarily due to increased North American demand for dairy.
• Vaccines sales increased 13% primarily due to continued growth of poultry products in Latin America and increased international demand, particularly in Southeast Asia.
• Gross profit increased $30.8 million, or 30%, with gross margin improving 260 basis points to 35.5%.
• Foreign currency losses, net, decreased significantly to $2.1 million from $11.7 million in the prior year period.
• Free cash flow was $47.3 million for the twelve months ended December 31, 2025.
• Gross leverage ratio of 3.1x as of December 31, 2025, indicating manageable debt.

Negatives

• Performance Products net sales decreased $1.6 million, or 10%, as a result of lower demand for ingredients used in personal care products.
• Performance Products gross profit decreased $0.6 million.
• Performance Products Adjusted EBITDA decreased $1.1 million, or 56%.
• Selling, general and administrative expenses (SG&A) increased $6.0 million, or 8%, primarily due to higher employee-related costs and a net increase of $1.9 million of costs associated with Phibro Forward income growth initiatives.
• Interest expense, net, increased $2.8 million due to higher average debt levels associated with the financing of the MFA acquisition and the expiration of a favorable interest rate swap agreement.
• Corporate expenses increased $3.7 million due to higher employee-related costs.

Risks

• Forward-looking statements are subject to risks and uncertainties, including with respect to any future debt and leverage levels, as detailed in the company's Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

Future Outlook

Phibro Animal Health Corporation has raised its fiscal year 2026 financial guidance, now expecting net sales between $1.45 billion and $1.50 billion (14% growth at midpoint) and Adjusted EBITDA between $245 million and $255 million (36% growth at midpoint). Diluted EPS is projected to be $2.08 to $2.32 (85% growth at midpoint), and Adjusted diluted EPS $2.93 to $3.10 (44% growth at midpoint). This updated guidance reflects confidence in continued momentum and progress across the business, despite global environmental challenges.

Management Comments

• "This was a strong quarter for us, and I'm really proud of how our teams are executing around the world." Jack Bendheim, President and Chief Executive Officer.
• "We're seeing faster than expected uptake of our newly integrated MFA portfolio, which is already giving our results a real lift." Jack Bendheim, President and Chief Executive Officer.
• "Our nutritional specialty and vaccine offerings continue to deliver strong, sustained growth across key markets." Jack Bendheim, President and Chief Executive Officer.
• "With this momentum and the progress we're making across the business, we feel confident raising our full year guidance." Jack Bendheim, President and Chief Executive Officer.
• "Even with some of the challenges in the global environment, our people continue to show resilience and stay focused on delivering for our customers." Jack Bendheim, President and Chief Executive Officer.
• "With the strategy we have in place and the dedication of our teams, I feel very good about where we're headed." Jack Bendheim, President and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Phibro's strong performance, particularly in its Animal Health segment, aligns with a broader trend of increasing demand for animal health products, driven by global population growth and rising protein consumption. The successful integration and faster-than-expected uptake of the MFA portfolio positions Phibro favorably against competitors by expanding its market reach and product offerings in a consolidating industry.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased net income, diluted EPS, and raised future guidance, potentially leading to increased share value.
• Employees: Increased employee-related costs suggest potential growth in headcount, particularly from the MFA acquisition, indicating job stability or creation.
• Customers: Continued strong growth in Animal Health, Nutritional Specialties, and Vaccines suggests successful product offerings and meeting customer demand.
• Creditors: Higher average debt levels due to acquisition financing, but a 3.1x gross leverage ratio indicates manageable debt relative to EBITDA.

Next Steps

• Host a webcast and conference call on February 5, 2026, at 9:00 AM Eastern to review financial results and respond to questions.
• Continue execution of the Phibro Forward income growth initiatives.

Key Dates

Recommendation

The company delivered exceptionally strong Q2 results, significantly exceeding prior-year performance across key metrics like net sales, net income, and Adjusted EBITDA. The successful integration of the MFA portfolio is driving substantial growth, and management's decision to raise full-year guidance demonstrates strong confidence in continued momentum. While increased debt and SG&A are noted, the overall financial health and growth trajectory, coupled with improved gross margins and reduced foreign currency losses, present a compelling investment case.

Keywords

Animal Health, Phibro, PAHC, Earnings, Q2 2026, Financial Results, Guidance, Adjusted EBITDA, Net Sales, MFA Acquisition, Veterinary, Livestock, Nutrition, Vaccines